CENERX NEWS & EVENTS

9-DEC-11

CeNeRx BioPharma Completes $4.85 Million Financing
Funds to Support Completion of Phase II Trial of TriRimaTM in Treatment Resistant Depression
Reports Good Progress in TriRima Phase II Trial and FDA Approval of IND to Assess CXB909 as Potential Treatment for Alzheimer's Disease
Read more...

8-FEB-11

CeNeRx Announces FDA IND Approval for Its Neuroprotective Agent in Chemotherapy-Induced Neuropathy and Results from First Human Study
Orally Active Enhancer of Human Nerve Growth Factor Has Demonstrated Promising Activity and Good Safety in Early Studies
CEO Barry Brand to Serve as Panelist on BIO CEO Therapeutic Workshop Panel
Read more...

1-JAN-11

CeNeRx Initiates Phase II Trial of TriRima™ as Monotherapy in Treatment Resistant Depression
Follows Successful Safety Studies of New and Improved Formulation of this Novel Antidepressant
Learn More about CeNeRx and TriRima at Biotech Showcase™ 2011
Read more...

02-NOV-10

CeNeRx's Novel Antidepressant Tririma™ Demonstrates Key Safety Benefit In Pivotal Safety Study

New Modified Release Formulation of Novel MAO Inhibitor Achieves Sustained High Levels of Drug Exposure While Showing No Signs of Cardiovascular Effects;
TriRima's Potential as First Monotherapy for Treatment Resistant Depression to be Tested in Phase II Trial Scheduled to Begin Later this Month;
Learn More about TriRima at Windhover's Therapeutic Area Partnerships Meeting as a 2011 "Top 10 Neuroscience Project to Watch"
Read more...

13-AUG-10

CeNeRx BioPharma Completes $13 Million Series C Financing
New Funds to Support Expanded Phase II Trial of Novel Antidepressant TriRima™
Read more...

12-JAN-10

New Clinical Study Shows Anxiolytic Potential of CeNeRx’s Novel Mechanism HPA Axis Modulator Compounds.

Hypothalamic-Pituitary-Adrenal (HPA) Axis Modulator CXB722 Demonstrates Promising Activity in Trier Social Stress Test;
Positive Study Results Confirm Distinctive Mechanism of Action and Set the Stage for Further Clinical Development of CXB722 Prodrug Ayrene
Read more...

07-DEC-09

Publication in Neuropsychopharmacology Confirms CeNeRx’s Novel RIMA Antidepressant TriRima™ Selectively and Reversibly Inhibits MAO-A.
Innovative PET Imaging Studies Confirm TriRima™ Demonstrates Reversible Inhibition of MAO-A in the Human Brain;
Represents First Validation in Humans of Mechanism of RIMA Antidepressants
Read more...

16-JUN-09

CeNeRx Biopharma Completes $9 Million Financing.

New Funds to Support Advancement of Multiple Novel Programs for CNS Disorders